Evaluating repetitive18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer
Authors:
- Maximilian P. SchmidMSMaximilian P. Schmid
- Richard PötterRPRichard Pötter
- Spyridoula KommataSKSpyridoula Kommata
- Dietmar GeorgDietmar Georg
- Dobrica LukicDLDobrica Lukic
- Robert DudczakRDRobert Dudczak
- Kurt KletterKKKurt Kletter
- Johannes DimopoulosJDJohannes Dimopoulos
- Georgios KaranikasGKGeorgios Karanikas
- Barbara BachtiaryBBBarbara Bachtiary
- 13 September 2010
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 49 (7) , 941-947
Abstract
Background. The aim of this pilot study was to assess tumour hypoxia in patients with cervical cancer before, during and after combined radio-chemotherapy and Magnetic Resonance Imaging (MRI) guided brachytherapy (BT) by use of the hypoxia Positron Emission Tomography (PET) tracer 18F-fluoroazomycin-arabinoside (18FAZA ). Material and methods. Fifteen consecutive patients with locally advanced cervical cancer referred for definitive radiotherapy (RT) were included in an approved clinical protocol. Stage distribution was 3 IB1, 1 IB2, 10 IIB, 1 IIIB, tumour volume was 55 cm3 (+/− 67, SD). Dynamic and static 18FAZA -PET scans were performed before, during and after external beam therapy (EBRT) and image guided BT +/− concomitant cisplatin. Dose was prescribed to the individual High Risk Clinical Target Volume (HR CTV) taking into account the dose volume constraints for adjacent organs at risk. Results. Five patients had visually identifiable tumours on 18FAZA -PET scans performed prior to radio-chemotherapy and four patients before brachytherapy. One of five 18FAZA PET positive patients had incomplete remission three months after RT, one had regional recurrence. Four of ten 18FAZA-PET negative patients developed distant metastases. The one patient with incomplete remission received 69 Gy (D90) in the HR CTV, whereas all other patients received mean 99 Gy (+/−12, SD). Conclusion. PET imaging with 18FAZA is feasible in patients with cancer of the uterine cervix. However, its predictive and prognostic value remains to be clarified. This applies in particular for the additional value of 18FAZA-PET compared to morphologic repetitive MRI within the setting of image guided high dose radiotherapy which may contribute to overcome hypoxia related radioresistance.Keywords
This publication has 22 references indexed in Scilit:
- Adaptive Management of Cervical Cancer RadiotherapySeminars in Radiation Oncology, 2010
- Dose–effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapyRadiotherapy and Oncology, 2009
- Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?Radiotherapy and Oncology, 2009
- Dose–Volume Histogram Parameters and Local Tumor Control in Magnetic Resonance Image–Guided Cervical Cancer BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Image-guided Adaptive Brachytherapy for Cervix CarcinomaClinical Oncology, 2008
- Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancerRadiotherapy and Oncology, 2007
- Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02Journal of Clinical Oncology, 2006
- Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center studyRadiotherapy and Oncology, 2005
- [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumorsNuclear Medicine and Biology, 2003
- Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix CancerJournal of Clinical Oncology, 2002